S100A11 as an immune-related exosomal driver of colorectal cancer progression: a novel diagnostic biomarker
S100A11 mechanistically promotes CRC progression by activating oncogenic signaling and reshaping the immune microenvironment, positioning it as a clinically relevant dual-function biomarker. The integration of bioinformatics, machine learning, and experimental validation underscores the potential of exosome-derived markers for immunotherapy and precision oncology. Future studies should focus on clinical validation and the development of exosome-based immune-targeted therapies for CRC management.
Authors
- Haibo Wang (ORCID: https://orcid.org/0000-0002-7514-1719)
- Jun He (ORCID: https://orcid.org/0000-0002-5998-5225)
- Rongchao He
- Liu Deng (ORCID: https://orcid.org/0000-0002-1392-6828)
- Zhong Shen (ORCID: https://orcid.org/0009-0001-4784-1830)
Institutions
- Anhui Medical University (CN)
- Third People's Hospital of Hangzhou (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-06-11
- DOI
- https://doi.org/10.3389/fonc.2025.1590128
- Citations
- 3
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 2.42